The long-term objective of the Mayo Center for Cell Signaling in Gastroenterology (MCCSG) is to understand the signaling pathways that control the function of gastrointestinal cells in health and disease. The Center members are organized into three Mechanistic Research Theme interest groups: i.) signal transduction;ii.) membrane receptors and ion channels;and, iii.) genetics and gene regulation. Each Mechanistic Research Theme represents an important area of signaling research that is an area of tremendous strength at Mayo Clinic. Our global hypothesis is that rapid advances in clinical care for patients with digestive diseases requires strong support of basic science research to identify disease mechanisms and intermediate biomarkers for digestive diseases, and that these basic science discoveries will generate translational research opportunities resulting in clinical trials. The Center goals are to promote and enhance cell signaling research by: i.) fostering collaborative, multidisciplinary research both by expanding the technical and collaborative capabilities of established Gl scientists and by attracting investigators from other disciplines;ii.) developing and implementing a robust and diverse Scientific Enrichment Program that includes seminars, workshops, symposia, a visiting faculty program, mini-sabbaticals, and web-based curricula;iii.) identifying and nurturing development of new Gl investigators via a rigorously peer-reviewed, widely publicized Pilot and Feasibility Program;and, iv.) promoting synergistic interaction between the signaling research base and the clinical research expertise of Mayo Gl investigators through activities that support signaling-related research and promote translation of basic science discoveries into clinical research. The Center seeks to support the three Mechanistic Research Themes by creating a supportive infrastructure that makes technologies more easily accessible, provides technical expertise to members from experts in a particular technology, uses existing resources efficiently, and develops novel methodologies through three linked biomedical Center Cores. The proposed biomedical cores are the: i.) Clinical Core;ii.) Genetics Core;and, iii.) Optical Microscopy Core. These Cores were developed by Center leadership in response to detailed and thoughtful analysis of barriers to cell signaling research and Center member surveys. The Core's specific goals are to: i.) develop and/or exploit advanced methods in biospecimen acquisition, processing, and annotation to enhance biospecimen collection and accessibility for Center investigators;ii.) enhance Center member's access to and implementation of current and emerging key genetic technologies;and, iii.) provide Center members with reliable access to state-of-the-art microscopic technology and expertise that will facilitate investigations of the pathogenesis of gastrointestinal and liver diseases.

Public Health Relevance

Gastrointestinal diseases and their complications have a significant affect on public health and health care utilization costs. Research supported by this Center grant, has the potential to improve care of patients afflicted with gastrointestinal disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK084567-03
Application #
8119015
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (M1))
Program Officer
Podskalny, Judith M,
Project Start
2009-09-01
Project End
2014-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
3
Fiscal Year
2011
Total Cost
$1,114,891
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Bandla, Harikrishna; Dasgupta, Debanjali; Mauer, Amy S et al. (2018) Deletion of endoplasmic reticulum stress-responsive co-chaperone p58IPK protects mice from diet-induced steatohepatitis. Hepatol Res 48:479-494
Guicciardi, Maria Eugenia; Trussoni, Christy E; Krishnan, Anuradha et al. (2018) Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 69:676-686
Mouchli, Mohamad A; Singh, Siddharth; Boardman, Lisa et al. (2018) Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. Inflamm Bowel Dis 24:1074-1081
Paradise, Brooke D; Barham, Whitney; Fernandez-Zapico, Martín E (2018) Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes? Cancers (Basel) 10:
Banales, Jesus M; Marzioni, Marco; LaRusso, Nicholas F et al. (2018) Cholangiocytes in health and disease: From basic science to novel treatments. Biochim Biophys Acta Mol Basis Dis 1864:1217-1219
Tarragó, Mariana G; Chini, Claudia C S; Kanamori, Karina S et al. (2018) A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab 27:1081-1095.e10
Kim, Minsoo; Druliner, Brooke R; Vasmatzis, Nikolaos et al. (2018) Inferring modes of evolution from colorectal cancer with residual polyp of origin. Oncotarget 9:6780-6792
Druliner, Brooke R; Wang, Panwen; Bae, Taejeong et al. (2018) Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. Sci Rep 8:3161
Mansini, Adrian P; Lorenzo Pisarello, Maria J; Thelen, Kristen M et al. (2018) MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma. Hepatology 68:561-573
Moncsek, Anja; Al-Suraih, Mohammed S; Trussoni, Christy E et al. (2018) Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice. Hepatology 67:247-259

Showing the most recent 10 out of 537 publications